Q3 Trade Pfizer
Q3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning, but overall, the fundamentals appear stable. This drop could present a buying opportunity if it’s mainly a liquidity grab
Note
28.8 needs some type of confirmation, whether it's a retest or very strong orders. This level is crucial for assessing the market's next moveNote
Small entry now 28.250Note
locked in 50% with a 1.3% gain x40 levrage. Holding rest BOS
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.